$2.61
-0.05 (-1.88%)
Open$2.68
Previous Close$2.66
Day High$2.72
Day Low$2.56
52W High$3.16
52W Low$0.96
Volume—
Avg Volume102.1K
Market Cap59.14M
P/E Ratio—
EPS$-2.86
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+367.0% upside
Current
$2.61
$2.61
Target
$12.19
$12.19
$8.12
$12.19 avg
$14.26
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 3.46M | 3.60M | 3.02M |
| Net Income | 357.4K | 374.4K | 370.1K |
| Profit Margin | 10.3% | 10.4% | 12.2% |
| EBITDA | 792.9K | 795.7K | 655.2K |
| Free Cash Flow | 311.9K | 219.4K | 229.2K |
| Rev Growth | +0.8% | +2.8% | +23.9% |
| Debt/Equity | 0.35 | 0.28 | 0.30 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |